Rebound Therapeutics raises $17m in Series B

Minimally invasive surgical device developer Rebound Therapeutics said today it closed a Series B round of financing, raising $16.5 million.

The round was led by HBM-MedFocus, Invus Opportunities Fund and Wexford Capital affiliates, the Irvine, Calif.-based company said. Funds from the round are slated to support product develpoment, regulatory approvals, scaling up manufacturing and commercialization efforts.

Rebound Threapeutics said it has developed a “unique array of devices to improve the procedural and clinical outcomes” of minimally invasive surgical procedures, and that device testing is scheduled to begin shortly

“We are very pleased to have the support from our investment partners as we build out our proprietary technology platform comprised of state-of-the-art imaging and illumination technologies for use during many Minimally Invasive Surgery procedures. When used together, our single-use, disposable MIS access and therapeutic devices will disrupt the way many MIS procedures are currently performed, including the displacement of the large, complex, capital equipment being used in operating rooms today. The Rebound platform technologies can be adapted for a variety of surgical procedures including neurosurgery, spine and orthopedic surgery, thoracic and general abdominal surgery. In these procedures, the Rebound technology may serve as a replacement for surgical microscopes, endoscopes, exoscopes and laparoscopes. The disposable products developed by Rebound will reduce the burdens of high capital equipment cost, operating room footprint, patient scheduling, maintenance and calibration expense, sterilization risks, procedural inefficiencies and user ergonomic hazards,” CEO & prez Jeffrey Valko said in a press release.

The post Rebound Therapeutics raises $17m in Series B appeared first on MassDevice.

from MassDevice http://ift.tt/2uTXzGU